Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Soquelitinib (CPI-818) in Peripheral T-cell Lymphomas. The expected timing is based on the latest available company guidance and may change.
Collab w/ Angel Pharmaceuticals. 02/08/24- Received FDA ODD. 8/1/24- FTD. 9/10/24- Ph3 initiated. 11/04/25:- Enrollment ongoing. 12/08/25:- Final Ph1/1b PTCL data at ASH 2025; strong responses and survival; Ph3 interim data in Late 2026. 03/12/26:- Registrational Ph3 PTCL trial NCT06561048 enrollment ongoing; ASH 2025 Ph1/1b data showed favorable PFS/OS and good tolerability. 05/07/26:- Registrational Ph3 PTCL trial enrollment ongoing; randomized 150-patient study versus chemotherapy with PFS primary endpoint. 08/06/26:- Registrational Ph3 PTCL trial enrollment remains on track; Late 2026 interim data preserved.
Verification
Confirm timing and program details against the company announcement or filing.